Oncology infographics gallery

Illustrations created with Grok Imagine. Click any graphic for the related explainer.

Subtopics: Precision oncology · Pillars of systemic therapy · Antibody–drug conjugates · History · Infographics

Precision oncology pathway — Precision oncology: test before you treat.

Antibody drug conjugate — Antibody–drug conjugate (e.g. trastuzumab deruxtecan), schematic.

History of cancer treatment — From shadows to light: history of cancer treatment.

Infographics

OrigAMI-4: subcutaneous amivantamab in pretreated head and neck squamous cell carcinoma — OrigAMI-4 · Rybrevant Faspro in pretreated HNSCC · Original Oncosphere graphic (8 Nov 2026)

EV-302: advanced urothelial cancer trial infographic — EV-302: advanced urothelial cancer · Original Oncosphere graphic

FLAURA2: EGFR-mutated lung cancer trial infographic — FLAURA2: EGFR-mutated lung cancer · Original Oncosphere graphic

DESTINY-Breast11: HER2-positive early breast cancer trial infographic — DESTINY-Breast11: HER2-positive early breast cancer · Original Oncosphere graphic

Organ-preservation pathway for MSI-H or dMMR rectal cancer — Dostarlimab organ-preservation pathway · Original Oncosphere graphic (5 Nov 2026)

Oncosphere · Trial brief

Dostarlimab · dMMR rectal cancer

Trial: Cercek et al., NEJM 2022 · Phase II, single arm

Arm: Dostarlimab for 6 months; planned chemoradiotherapy and surgery could be omitted following clinical complete response.

Key endpoints: Sustained clinical complete response or pathological complete response; overall response.

12/12 clinical complete responses

Initial report among patients completing treatment with ≥6 months of follow-up. Small early cohort; not a randomized comparison.

Original Oncosphere graphic · Source: Cercek et al., NEJM 2022, doi:10.1056/NEJMoa2201445

Oncosphere · Evidence map

First-line systemic therapy · pillars

Trials: Evidence spans tumour-specific randomized trials; this card is a framework, not a single study.

Arms: Cytotoxic chemotherapy · endocrine therapy · biomarker-directed targeted therapy · immunotherapy; combinations depend on disease and biomarkers.

Key endpoints: Overall survival · progression-free survival · response · quality of life · toxicity.

Test biomarkers first. Match tumour, patient fitness and treatment goals to the relevant published trial.

Original Oncosphere graphic · See linked explainer for individual trials and sources.